Elimination of bla
Antimicrobial resistance
CRISPR-Cas9
Klebsiella pneumoniae
bla KPC−2
Journal
BMC microbiology
ISSN: 1471-2180
Titre abrégé: BMC Microbiol
Pays: England
ID NLM: 100966981
Informations de publication
Date de publication:
26 10 2023
26 10 2023
Historique:
received:
27
06
2023
accepted:
11
10
2023
medline:
30
10
2023
pubmed:
27
10
2023
entrez:
26
10
2023
Statut:
epublish
Résumé
The purpose of this study is to re-sensitive bacteria to carbapenemases and reduce the transmission of the bla The single guide RNA (sgRNA) specifically targeted to the bla In the present study, we constructed a specific prokaryotic CRISPR-Cas9 system plasmid targeting cleavage of the bla In conclusion, our study demonstrated that the one plasmid-mediated CRISPR-Cas9 system can be used as a novel tool to remove resistance plasmids and re-sensitize the recipient bacteria to antibiotics. This strategy provided a great potential to counteract the ever-worsening spread of the bla
Identifiants
pubmed: 37884864
doi: 10.1186/s12866-023-03058-7
pii: 10.1186/s12866-023-03058-7
pmc: PMC10601263
doi:
Substances chimiques
Anti-Bacterial Agents
0
Bacterial Proteins
0
beta-Lactamases
EC 3.5.2.6
Carbapenems
0
RNA, Guide, CRISPR-Cas Systems
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
310Informations de copyright
© 2023. The Author(s).
Références
Nat Biotechnol. 2014 Nov;32(11):1141-5
pubmed: 25240928
Theranostics. 2021 Mar 13;11(11):5464-5490
pubmed: 33859758
Nucleic Acids Res. 2021 May 21;49(9):5216-5229
pubmed: 33885789
Antimicrob Agents Chemother. 2020 Aug 20;64(9):
pubmed: 32631827
Infect Drug Resist. 2020 Apr 22;13:1171-1178
pubmed: 32368108
Front Microbiol. 2021 Jun 10;12:536357
pubmed: 34177818
Emerg Infect Dis. 2019 Oct;25(10):1861-1867
pubmed: 31538558
Ann Clin Microbiol Antimicrob. 2019 Jul 5;18(1):21
pubmed: 31277669
Biomed Res Int. 2021 Apr 08;2021:6614812
pubmed: 33928150
Front Cell Infect Microbiol. 2019 Aug 08;9:281
pubmed: 31440476
Nat Biotechnol. 2014 Mar;32(3):279-284
pubmed: 24463574
Indian J Med Res. 2021 Mar;154(3):520-526
pubmed: 35345078
Front Microbiol. 2016 Feb 19;7:173
pubmed: 26925045
Front Microbiol. 2022 Mar 31;13:859854
pubmed: 35432284
PLoS Pathog. 2018 Jun 14;14(6):e1006990
pubmed: 29902258
Infect Drug Resist. 2020 Apr 20;13:1111-1121
pubmed: 32368102
Front Microbiol. 2019 Aug 27;10:1933
pubmed: 31507555
Nat Biotechnol. 2016 Feb;34(2):184-191
pubmed: 26780180
J Microbiol Biotechnol. 2016 Feb;26(2):394-401
pubmed: 26502735
Proc Natl Acad Sci U S A. 2015 Jun 9;112(23):7267-72
pubmed: 26060300
Sci Rep. 2017 Mar 21;7:44929
pubmed: 28322317
Microb Genom. 2017 Jul 4;3(7):e000114
pubmed: 29026655
Sci Rep. 2016 Nov 24;6:37895
pubmed: 27883076
EBioMedicine. 2017 May;19:98-106
pubmed: 28479289
Front Pharmacol. 2018 Jul 12;9:749
pubmed: 30050439
Plant Biotechnol J. 2020 Mar;18(3):721-731
pubmed: 31452351
mSystems. 2020 Feb 4;5(1):
pubmed: 32019835
Mol Ther Nucleic Acids. 2015 Nov 17;4:e264
pubmed: 26575098
Antimicrob Agents Chemother. 2019 Oct 22;63(11):
pubmed: 31527030
Integr Biol (Camb). 2017 Feb 20;9(2):109-122
pubmed: 28045163
Adv Drug Deliv Rev. 2021 Sep;176:113891
pubmed: 34324887
Mar Life Sci Technol. 2020 Feb;2(1):1-5
pubmed: 33313574
Int J Mol Sci. 2020 Feb 07;21(3):
pubmed: 32046217
J Oral Microbiol. 2022 Jan 02;14(1):2008153
pubmed: 34992734
Nat Biotechnol. 2014 Nov;32(11):1146-50
pubmed: 25282355
mSystems. 2022 Feb 22;7(1):e0116921
pubmed: 35014866
J Biotechnol. 2017 Jan 10;241:136-146
pubmed: 27845164
Methods Enzymol. 2013;529:329-36
pubmed: 24011059
Antimicrob Agents Chemother. 2017 Mar 24;61(4):
pubmed: 28167547
Sci Rep. 2016 Jun 24;6:28566
pubmed: 27338021
Nucleic Acids Res. 2021 Jan 11;49(1):584-594
pubmed: 33332569
Bioinformatics. 2017 Nov 15;33(22):3642-3644
pubmed: 28961776
Nat Microbiol. 2019 Nov;4(11):1919-1929
pubmed: 31358985
Antibiotics (Basel). 2021 Dec 22;11(1):
pubmed: 35052889